Quick Order

CD89 / FCAR Antibody, Rabbit PAb, Antigen Affinity Purified

    DatasheetReviewsRelated ProductsProtocols
    Human CD89/FCAR Antibody Product Information
    Immunogen:Recombinant Human CD89 protein (Catalog#10414-H08H)
    Clone ID:
    Ig Type:Rabbit IgG
    Concentration:
    Formulation:0.2 μm filtered solution in PBS with 5% trehalose
    Preparation:Produced in rabbits immunized with purified, recombinant Human CD89 / FCAR (rh CD89; Catalog#10414-H08H; NP_001991.1; Met 1-Asn 227). CD89 specific IgG was purified by human CD89 affinity chromatography.
    Other CD89/FCAR Antibody Products
    CD89/FCAR Background

    FCAR, also called FcαRI or CD89, is a type I  transmembrane receptor for Fc region of IgA which is the most abundant immunoglobulin in mucosal areas but is only the second most common antibody isotype in serum. This receptor is present on the surface of myeloid lineage cells such as neutrophils, monocytes, macrophages, and eosinophils, especially phagocytes located in mucosal areas. Upon ligand IgA binding, FcαRI associates with the FcR γ signaling molecule bearing the immunoreceptor tyrosine-based activation motif (ITAM) through a unique charge-based mechanism and triggers multiple cell-mediated immune responses. It has been reported that Fc RI is a dual-function receptor that can mediate both inflammatory and anti-inflammatory responses depending on the type of interaction with its ligand. Sustained aggregation of FCAR results in activation of target-cell functions such as antigen presentation and cytokine release. In contrast, Monomeric targeting with serum IgA or with a variety of anti-FcαRI Fab fragments triggers an inhibitory response and additionally induces apoptosis. FcαRI thus play an fundamental role in preventing tumor development and growth, as well as in controlling inflammation.

    Human CD89/FCAR References
    1. Maliszewski, C.R. et al., 1990, J. Exp. Med. 172: 1665-1672.
    2. Launay, P. et al., 1999, J. Biol. Chem. 274: 7216-7225.
    3. Monteiro, R.C. et al., 2003, Annu. Rev. Immunol. 21: 177-204.
    4. Otten, M.A. et al., 2005, J. Immunol. 174: 5472-5480.
    5. Pasquier, B. et al., 2005, Immunity. 22:31-42.
    6. Kanamaru, Y. et al., 2007, Blood. 109: 203-211.
    Product nameProduct name
    All information of our products is subject to change without notice. Please refer to COA enclosed in shipped package for the newest information.
    Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"